EDIT - Editas Medicine, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.43
-0.51 (-1.76%)
As of 2:51PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close28.94
Open28.59
Bid28.52 x 1000
Ask28.65 x 3100
Day's Range28.28 - 29.35
52 Week Range23.83 - 45.02
Volume201,860
Avg. Volume695,289
Market Cap1.35B
Beta (3Y Monthly)3.20
PE Ratio (TTM)N/A
EPS (TTM)-2.65
Earnings DateMar 4, 2019 - Mar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.29
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEventsyesterday

    Edited Transcript of EDIT earnings conference call or presentation 7-Nov-18 10:00pm GMT

    Q3 2018 Editas Medicine Inc Earnings Call

  • InvestorPlace4 days ago

    Why CRSP Stock Has Added Layers of Risk

    Biotech stocks like CRISPR Therapeutics (NASDAQ:CRSP) are inherently risky, and inherently volatile. CRISPR stock itself, only public for a little over two years, is a good example. CRSP stock went public at $14 — and cleared $70 this year.

  • Here's Why Editas Medicine Jumped 23% in November
    Motley Fool4 days ago

    Here's Why Editas Medicine Jumped 23% in November

    The gene-editing pioneer reported third-quarter 2018 earnings and reported FDA acceptance of its first investigational new drug (IND) application.

  • GlobeNewswire4 days ago

    Editas Medicine Names Cynthia Collins to Board of Directors

    Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of Directors. Ms. Collins is a recognized leader in cell and gene therapy, molecular diagnostics, life sciences, and therapeutics. Prior to her most recent position as CEO of Human Longevity, Inc., she served as the CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics.

  • Is Editas Medicine a Buy?
    Motley Fool5 days ago

    Is Editas Medicine a Buy?

    There's a long way to go for this biotech. But there could also be a huge payoff if all goes well.

  • GlobeNewswire12 days ago

    Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia

    Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for the treatment of sickle cell disease and beta-thalassemia. In these experiments, the Company demonstrated HBG1/2 promoter-edited CD34+ cells robustly engrafted in mice without lineage skewing of red blood cell precursors. The Company reported these data today in an oral presentation at the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego.

  • Better Buy: Editas Medicine vs. Sangamo Therapeutics
    Motley Fool12 days ago

    Better Buy: Editas Medicine vs. Sangamo Therapeutics

    Gene editing comes in different flavors. Which of these gene-editing biotech stocks is tastier?

  • This Biotech Stock Could Launch Its First CRISPR Drug In 2022
    Investor's Business Daily14 days ago

    This Biotech Stock Could Launch Its First CRISPR Drug In 2022

    Crispr Therapeutics will launch a gene-editing therapy in the U.S. in 2022, an analyst predicted Friday as he initiated coverage with a buy rating.

  • Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018
    Motley Fool14 days ago

    Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018

    The gene-editing specialist has been a rare bright spot within the hard hit biotech space this year. Here's why.

  • FDA clears Editas to test gene-editing drug in humans
    American City Business Journals14 days ago

    FDA clears Editas to test gene-editing drug in humans

    The study, which Editas said will involve 10 to 20 patients, will be the second company-sponsored clinical trial in the U.S. of a drug based on CRISPR/Cas9 technology.

  • GlobeNewswire14 days ago

    Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101

    CAMBRIDGE, Mass., Nov. 30, 2018 (GLOBE NEWSWIRE) --  Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10 (LCA10). “The FDA’s acceptance of our IND for EDIT-101 is a significant moment in the field of genome editing, and importantly, a critical milestone for patients, as we are now one step closer to a treatment for LCA10,” said Katrine Bosley, President and Chief Executive Officer, Editas Medicine.

  • Mass. biotech leaders voice alarm over report of first gene-edited babies
    American City Business Journals18 days ago

    Mass. biotech leaders voice alarm over report of first gene-edited babies

    The researcher's claims, which have not yet been published in a scientific paper, prompted a swift outcry among Boston-area life sciences officials Monday, given that such genetic changes can be passed on to future generations.

  • Analyzing Editas Medicine’s Operational Performance
    Market Realist28 days ago

    Analyzing Editas Medicine’s Operational Performance

    Editas Medicine (EDIT) incurred general and administrative expenses of $13.33 million in the third quarter—compared to $12.63 million in the third quarter of 2017. The increase was due to higher stock-based compensation and employee-related expenses during this period.

  • Editas Stock: Analysts’ Recommendations
    Market Realist28 days ago

    Editas Stock: Analysts’ Recommendations

    In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.” The mean rating for Editas Medicine stock is 2.4 with a target price of $47.29, which implies an upside potential of 75.8% over Editas Medicine’s closing price of $26.9 on November 14.

  • Who’s Eyeing Editas Medicine?
    Market Realist28 days ago

    Who’s Eyeing Editas Medicine?

    Editas Medicine (EDIT) is a leading genome editing company. The company’s product development strategy is to mainly target genetically defined diseases with a focus on debilitating illnesses.

  • A Financial Overview of CRISPR Therapeutics in November
    Market Realistlast month

    A Financial Overview of CRISPR Therapeutics in November

    CRISPR Therapeutics (CRSP) reported revenues of $563,000 in the third quarter—compared to $2.4 million in the third quarter of 2017. CRISPR Therapeutics reported net revenues of $3.0 million over the first nine months of 2018—compared to $8.7 million during the same period in 2017. CRISPR Therapeutics’ net revenues are mainly from collaborations undertaken by the company.

  • CRISPR Therapeutics: Analysts’ View in November
    Market Realistlast month

    CRISPR Therapeutics: Analysts’ View in November

    On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8. On November 7, after the company reported its third-quarter financial results, the stock price grew ~10.81% to $38.85 from the close of $35.06 on November 6.

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within IDEXX Laboratories, Editas Medicine, Arconic, Cardtronics, Cloudera, and BMC Stock — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Editas Medicine Makes Steady Progress in Another Solid Quarter
    Motley Foollast month

    Editas Medicine Makes Steady Progress in Another Solid Quarter

    From filing its IND filing for EDIT-101 to new data on new engineered cell treatments, the genome editing company delivered just as promised in Q3.

  • Cambridge's Editas asks FDA to start gene editing trial
    American City Business Journalslast month

    Cambridge's Editas asks FDA to start gene editing trial

    Editas Medicine could be the next to test the widely watched gene editing technology CRISPR/Cas9 after filing a clinical trial application late last month, the company revealed Wednesday.

  • Editas Medicine, Inc. (EDIT) Q3 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Editas Medicine, Inc. (EDIT) Q3 2018 Earnings Conference Call Transcript

    EDIT earnings call for the period ending September 30, 2018.

  • Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
    Zackslast month

    Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates

    Editas (EDIT) delivered earnings and revenue surprises of 55.56% and 120.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Editas: 3Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 32 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...

  • GlobeNewswirelast month

    Editas Medicine Announces Third Quarter 2018 Results and Update

    Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual.

  • Here's Why CRISPR Stocks Fell as Much as 40.7% in October
    Motley Foollast month

    Here's Why CRISPR Stocks Fell as Much as 40.7% in October

    It was a busy month for gene editing stocks, which suffered from both CRISPR-specific news and the broader stock market's fall.